Trials / Completed
CompletedNCT02957682
Evaluating Effect of the Study Drug Praluent (Alirocumab) on Neurocognitive Function When Compared to Placebo
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Praluent on Neurocognitive Function in Patients With Heterozygous Familial Hypercholesterolemia or With Non-Familial Hypercholesterolemia at High and Very High Cardiovascular Risk
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 2,176 (actual)
- Sponsor
- Regeneron Pharmaceuticals · Industry
- Sex
- All
- Age
- 40 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to evaluate the effect on mental state (known as "neurocognitive function") with use of Praluent.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Praluent (Alirocumab) | |
| DRUG | Placebo |
Timeline
- Start date
- 2016-11-02
- Primary completion
- 2020-03-05
- Completion
- 2020-03-05
- First posted
- 2016-11-08
- Last updated
- 2021-05-07
- Results posted
- 2021-05-07
Locations
188 sites across 9 countries: United States, Bulgaria, Chile, Estonia, Japan, Mexico, Russia, South Africa, Ukraine
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02957682. Inclusion in this directory is not an endorsement.